EyePoint Pharmaceuticals Forms Executive Scientific Advisory Board

EyePoint Pharmaceuticals announced the formation of its Executive Scientific Advisory Board (SAB), chaired by Carl Regillo MD, FACS, Chief of the Retina Service at Wills Eye Hospital.

Other members of the SAB include Sophie J. Bakri, MD, Mayo Clinic; Caroline R. Baumal, MD, Tufts Medical Center; David S. Boyer, MD, University of Southern California Keck School of Medicine; Glenn J. Jaffe, MD, Duke University; Rishi P. Singh, MD, Cleveland Clinic; and Charles C. Wykoff, MD, PhD, Retina Consultants of Texas. These prominent retinal surgeons and leaders in the field of vision will work with EyePoint management to advance a pipeline of ocular products that advance the treatment paradigm for better patient outcomes.

“We are very honored to have such distinguished and talented experts sit on EyePoint Pharmaceuticals’ executive scientific advisory board,” Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, said in a company news release. “And it is a testament to the quality of our science and pipeline potential that they are now advising us. Their combined knowledge, insight, experience, and strategic council will prove vital as we approach interim 6-month data for our phase 1 DAVIO trial of EYP-1901 for the potential treatment of wet-AMD and continue to advance our innovative pipeline of treatments for patients with serious ophthalmic diseases.”

Additional background information on the SAB members can be found at www.eyepointpharma.com